Molecular Imaging 2017

The PROMIS study

 576 men  MP-MRI followed by TRUS-biopsy (standard practice) & TPM- biopsy (reference standard)  Clinically significant cancer:  MP-MRI versus TRUS-biopsy:

 Sensitivity: 93% vs 48%  Specificity: 41% vs 96%

Ahmed HU et al. PROMIS study group. Lancet 2017;389(10071):815-822 Kapoor J et al. Eur Urol. 2017 Feb 23. pii: S0302-2838(17)30103-3.